Results 41 to 50 of about 2,234,624 (258)

Oxaliplatin: Preclinical perspectives on the mechanisms of action, response and resistance [PDF]

ecancermedicalscience, 2010
Oxaliplatin is a third-generation platinum compound that has shown a wide range of anti-tumour activity in metastatic cancer and in multiple cell lines. It contains a diaminocyclohexane carrier ligand and is one of the least toxic platinum agents. In the past decade, the use of oxaliplatin for the treatment of colorectal cancer has become increasingly ...
Seetharam, RN, Sood, A, Goel, S
openaire   +2 more sources

Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer [PDF]

, 2013
Background: Preoperative radiochemotherapy (RCT) with 5-FU or capecitabine is the standard of care for patients with locally advanced rectal cancer (LARC). Preoperative RCT achieves pathological complete response rates (pCR) of 10-15%.
Erik Engel, Engel, Erik, Jürgen Dunst, Florian Würschmidt, Kathrin Dellas, Arnold, Dirk, Dirk Arnold, Michael Richter, Richter, Michael, Rödel, Claus, Thomas Reese, Höhler, Thomas, Thomas Höhler, Claus Rödel, Dellas, Kathrin, Reese, Thomas, Wagner, Wolfgang, Dunst, Jürgen, Würschmidt, Florian, Wolfgang Wagner   +19 more
core   +1 more source

Evidence for Two Modes of Synergistic Induction of Apoptosis by Mapatumumab and Oxaliplatin in Combination with Hyperthermia in Human Colon Cancer Cells [PDF]

, 2013
Colorectal cancer is the third leading cause of cancer-related mortality in the world-- the main cause of death from colorectal cancer is hepatic metastases, which can be treated with isolated hepatic perfusion (IHP).
Yong J. Lee, Yong J. Lee (297943), Song, X, Lee, YJ, Seog-Young Kim, Song Xinxin, Xinxin Song, Kim Seog-Young, Yong J Lee, Xinxin Song (297942), Song, Xinxin, Lee Yong J., Kim, Seog-Young, Seog-Young Kim (297940), Kim, SY, Calogero, Raffaele A, Lee, Yong J.   +16 more
core   +2 more sources

Upregulation of CRABP2 by TET1-mediated DNA hydroxymethylation attenuates mitochondrial apoptosis and promotes oxaliplatin resistance in gastric cancer

Cell Death and Disease, 2022
Oxaliplatin is the main chemotherapy drug for gastric cancer (GC), but quite a few patients are resistant to oxaliplatin, which contributes to the poor prognosis of GC patients.
Xiaolong Tang, Yahang Liang, Guorui Sun, Qingsi He, Zhenyu Hou, Xingzhi Jiang, Peng Gao, Hui Qu   +7 more
doaj   +1 more source

Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction [PDF]

, 2013
Background: This phase I/II-trial assessed the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of neoadjuvant radiochemotherapy (RCT) with docetaxel and oxaliplatin in patients with locally advanced adenocarcinoma of the oesophagogastric ...
Klautke, Gunther, Galle, Peter R., Brenner, Baruch, Arnold, Dirk, Roessler, Hans-Peter, Thomaidis, Thomas, Schimanski, Carl Christoph, Schmidberger, Heinz, Rödel, Claus, Gockel, Ines, Möhler, Markus, Trarbach, Tanja, Lang, Hauke   +12 more
core   +1 more source

A role for ceramide glycosylation in resistance to oxaliplatin in colorectal cancer

Experimental Cell Research, 2020
There is growing evidence to support a role for the ceramide-metabolizing enzyme, glucosylceramide synthase (GCS), in resistance to a variety of chemotherapeutic agents. Whether GCS contributes to oxaliplatin resistance in colorectal cancer (CRC) has not yet been determined.
James P, Madigan, Robert W, Robey, Joanna E, Poprawski, Huakang, Huang, Christopher J, Clarke, Michael M, Gottesman, Myles C, Cabot, Daniel W, Rosenberg   +7 more
openaire   +3 more sources

Role of lncSLCO1C1 in gastric cancer progression and resistance to oxaliplatin therapy

Clinical and Translational Medicine, 2022
AbstractBackgroundGastric carcinoma (GC) is one of the most deadly diseases due to tumour metastasis and resistance to therapy. Understanding the molecular mechanism of tumour progression and drug resistance will improve therapeutic efficacy and develop novel intervention strategies.MethodsDifferentially expressed long non‐coding RNAs (lncRNAs) in ...
Yu‐Feng Xiao, Bo‐Sheng Li, Jing‐Jing Liu, Su‐Min Wang, Jiao Liu, Huan Yang, Yi‐Yang Hu, Chun‐Li Gong, Ji‐Liang Li, Shi‐Ming Yang   +9 more
openaire   +3 more sources

Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells [PDF]

, 2006
Cisplatin produces good responses in solid tumours including small cell lung cancer (SCLC) but this is limited by the development of resistance. Oxaliplatin is reported to show activity against some cisplatin-resistant cancers but there is little known ...
Stordal, Britta K, Stordal, BK, Ross A. Davey, Davey, Mary W., Davey, RA, Davey, Mary W, Britta K. Stordal, Davey, Ross, Mary W. Davey, Stordal, B, Stordal, Britta, Davey, MW, Davey, R., Stordal, B., Davey, M.   +14 more
core   +4 more sources

ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair [PDF]

, 2008
Background: The H69CIS200 and H69OX400 cell lines are novel models of low-level platinum-drug resistance. Resistance was not associated with increased cellular glutathione or decreased accumulation of platinum, rather the resistant cell lines have a cell
Davey, Ross, Stordal, Britta, Stordal, B., Davey, R.   +3 more
core   +2 more sources

Cross resistance between cisplatin and oxaliplatin in a low-level resistance lung cancer cell model

, 2005
Oxaliplatin is thought to have activity against cisplatin resistant cancers and has fewer side effects than cisplatin. An understanding of the cellular and molecular reasons for this advantage would lead to further treatment improvements. A lack of cross
Stordal, B., Davey, M., Davey, R.
core   +4 more sources